Chiasma closes $70 million Series E financing round Chiasma.

The company intends to send a New Drug Software to the U.S. Food and Drug Administration for octreotide capsules in the second one fourth of 2015 and, if the NDA is authorized, to launch the product in the U.S. Thereafter soon. If authorized, octreotide capsules will be the initial and only oral somatostatin analog, providing another option to patients receiving painful shots. ‘The dedication from both brand-new and existing investors provide us with the resources to progress our regulatory efforts, prepare for a successful release of octreotide capsules, check oral octreotide capsules for additional indications and further invest in earlier-stage TPE programs that may fuel our growth over the future,’ stated Roni Mamluk, Ph.D., ceo of Chiasma.From a cost perspective, there are definite advantages, and in the current economic climate, these are undeniably attractive to us and to trial sponsors. As in additional CEE countries like Poland and Ukraine Just, we are seeing very encouraging levels of interest in conducting more trials in Hungary. .. Can I Drink Tap Water While I’m Pregnant? Ever since I became pregnant, I have been drinking water in bottles because I’ve heard that drinking water during pregnancy is unhealthy.